Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma (SIMPLY)
SIMulation-free Protocols for Lymphoma RadiotherapY [SIMPLY]
This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.
The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.
Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.
On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.
The study includes two cohorts:
Participants with orbital or ocular adnexal indolent B-cell lymphoma.
Participants with non-orbital indolent B-cell lymphoma.
If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.
The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.
Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Mahmood AminiLari, PhD
- Номер телефона: 6522 4169464501
- Электронная почта: mahmood.aminilari@uhn.ca
Места учебы
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 1X6
- Рекрутинг
- Princess Margaret Cancer Centre, University Health Network
-
Контакт:
- Mahmood AminiLari, PhD
- Номер телефона: 6522 4169464501
- Электронная почта: mahmood.aminilari@uhn.ca
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Histologically confirmed indolent B-cell lymphoma, including marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma grades 1-2, small lymphocytic lymphoma, or mantle cell lymphoma.
- Disease requiring focal radiation therapy with 4 Gy delivered in one fraction for local control or symptom relief.
- Lesion anatomy suitable for single-fraction radiation therapy and simulation-free, CBCT-guided treatment delivery, as determined by the treating radiation oncologist.
- Available diagnostic CT imaging suitable for contouring and dose calculation that encompasses the full intended target and relevant organs at risk:
- Obtained within 2 months before treatment for orbital or ocular adnexal disease.
- Obtained within 6 weeks before treatment for non-orbital disease.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, with the ability to tolerate treatment positioning and delivery.
- Localized or advanced-stage disease is permitted, provided the target lesion is appropriate for focal treatment.
Exclusion Criteria:
- Diagnostic imaging that does not meet the minimum quality requirements for treatment planning or falls outside the required time window.
- Disease anatomy unsuitable for simulation-free delivery, such as inability to maintain stable positioning, excessive motion, or inadequate CBCT visualization.
- Prior radiation therapy to the same site if re-irradiation using the study workflow is considered clinically inappropriate.
- Bulky disease greater than 6 centimeters for which single-fraction 4 Gy radiation therapy is unlikely to provide adequate local control, as determined by the treating physician.
- Requirement for urgent systemic therapy because of widespread or symptomatic disease.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Simulation-Free Single-Fraction Radiation Therapy
Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment. |
Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Successful Completion of Simulation-Free Radiation Therapy
Временное ограничение: Periprocedural (single radiation treatment session)
|
Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation. |
Periprocedural (single radiation treatment session)
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time From Radiation Oncology Consultation to Treatment
Временное ограничение: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
|
Number of calendar days between the radiation oncology consultation date and the date of radiation treatment. |
From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
|
|
Same-Day Treatment
Временное ограничение: Day 1 (date of radiation oncology consultation)
|
Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation. |
Day 1 (date of radiation oncology consultation)
|
|
Total On-Couch Time
Временное ограничение: Periprocedural (single radiation treatment session)
|
Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery. |
Periprocedural (single radiation treatment session)
|
|
Number of Hospital Visits
Временное ограничение: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
|
Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow. |
From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
|
|
CT Simulation Avoided
Временное ограничение: Periprocedural (through completion of the single radiation treatment session)
|
Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment. |
Periprocedural (through completion of the single radiation treatment session)
|
|
Reasons for Simulation-Free Workflow Failure
Временное ограничение: From treatment planning through radiation treatment completion, up to 4 weeks
|
Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan. |
From treatment planning through radiation treatment completion, up to 4 weeks
|
|
Clinician-Graded Treatment-Related Toxicity
Временное ограничение: Baseline, 2-4 weeks, and 3 months after treatment
|
Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Ocular Surface Disease Index Score
Временное ограничение: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Head and Neck Quality-of-Life Symptoms
Временное ограничение: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Index Symptom Severity
Временное ограничение: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Local Control of the Treated Site
Временное ограничение: 6 months after radiation treatment
|
Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination. |
6 months after radiation treatment
|
|
Retreatment of the Treated Site
Временное ограничение: Within 12 months after radiation treatment
|
Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site. |
Within 12 months after radiation treatment
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования
- Хроническое заболевание
- Атрибуты болезни
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лимфатические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Лимфома, неходжкинская
- Лейкемия, В-клеточная
- Лимфома, В-клеточная
- Лимфома
- Лейкемия, лимфоидная
- Лейкемия
- Патологические состояния, признаки и симптомы
- Гемики и лимфатические заболевания
- Лейкемия, лимфоцитарная, хроническая, B-клеточная
- Лимфома, фолликулярная
- Лимфома, мантийно-клеточная
- Лимфома, B-клетки, маргинальная зона
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- 26-5319
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .